These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8615146)

  • 1. Visual evoked potentials and spatiotemporal contrast sensitivity changes in idiopathic Parkinson's disease and multiple system atrophy.
    Delalande I; Destée A; Hache JC; Forzy G; Bughin M; Benhadjali J
    Adv Neurol; 1996; 69():319-25. PubMed ID: 8615146
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of L-DOPA on spatiotemporal contrast sensitivity in Parkinson's disease.
    Mestre DR; Blin O; van den Brand CL; Azulay JP; Serratrice G
    Adv Neurol; 1996; 69():503-11. PubMed ID: 8615172
    [No Abstract]   [Full Text] [Related]  

  • 3. Do visual-evoked potentials and spatiotemporal contrast sensitivity help to distinguish idiopathic Parkinson's disease and multiple system atrophy?
    Delalande I; Hache JC; Forzy G; Bughin M; Benhadjali J; Destée A
    Mov Disord; 1998 May; 13(3):446-52. PubMed ID: 9613735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poor visual discrimination and visual hallucinations in Parkinson's disease.
    Diederich NJ; Goetz CG; Raman R; Pappert EJ; Leurgans S; Piery V
    Clin Neuropharmacol; 1998; 21(5):289-95. PubMed ID: 9789709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recognition of category-related visual stimuli in Parkinson's disease: before and after pharmacological treatment.
    Righi S; Viggiano MP; Paganini M; Ramat S; Marini P
    Neuropsychologia; 2007 Oct; 45(13):2931-41. PubMed ID: 17662314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical diagnosis of multiple system atrophy presenting as pure parkinsonism.
    Albanese A; Colosimo C; Lees AJ; Tonali P
    Adv Neurol; 1996; 69():393-8. PubMed ID: 8615156
    [No Abstract]   [Full Text] [Related]  

  • 7. [Parkinson "plus"].
    Fabre N; Brefel-Courbon C; Rascol O
    Rev Prat; 1997 May; 47(10):1077-82. PubMed ID: 9208670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinicopathologic spectrum of Lewy body disease.
    Mark MH; Dickson DW; Sage JI; Duvoisin RC
    Adv Neurol; 1996; 69():315-8. PubMed ID: 8615145
    [No Abstract]   [Full Text] [Related]  

  • 9. Abnormal excitability of premotor-motor connections in de novo Parkinson's disease.
    Buhmann C; Gorsler A; Bäumer T; Hidding U; Demiralay C; Hinkelmann K; Weiller C; Siebner HR; Münchau A
    Brain; 2004 Dec; 127(Pt 12):2732-46. PubMed ID: 15509619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Utility of the study of the vegetative nervous system in the differential diagnosis between Parkinson's disease and multiple system atrophy].
    Rouco I; Gómez JC; Lezcano E; Aniel-Quiroga MA; Velasco F; Barcena J; Pérez Bas M; Hurtado P; Cruz Lachén M; Zarranz JJ
    Neurologia; 2006 Apr; 21(3):119-23. PubMed ID: 16575624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversible dissociation of sensitivity to dynamic stimuli in Parkinson's disease: is magnocellular function essential to reading motion-defined letters?
    Giaschi D; Lang A; Regan D
    Vision Res; 1997 Dec; 37(24):3531-4. PubMed ID: 9425528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Visual dysfunction in Parkinson disease without dementia.
    Uc EY; Rizzo M; Anderson SW; Qian S; Rodnitzky RL; Dawson JD
    Neurology; 2005 Dec; 65(12):1907-13. PubMed ID: 16282276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levodopa therapy for Parkinson's disease: challenges and future prospects.
    Olanow CW; Lees A; Obeso J
    Mov Disord; 2008; 23 Suppl 3():S495-6. PubMed ID: 18781670
    [No Abstract]   [Full Text] [Related]  

  • 14. Parkinson's disease.
    Clarke CE; Moore AP
    Am Fam Physician; 2007 Apr; 75(7):1045-8. PubMed ID: 17427619
    [No Abstract]   [Full Text] [Related]  

  • 15. Three-dimensional gait biomechanics in Parkinson's disease: evidence for a centrally mediated amplitude regulation disorder.
    Morris M; Iansek R; McGinley J; Matyas T; Huxham F
    Mov Disord; 2005 Jan; 20(1):40-50. PubMed ID: 15390033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
    Prescott IA; Dostrovsky JO; Moro E; Hodaie M; Lozano AM; Hutchison WD
    Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Slowing of oscillatory brain activity is a stable characteristic of Parkinson's disease without dementia.
    Stoffers D; Bosboom JL; Deijen JB; Wolters EC; Berendse HW; Stam CJ
    Brain; 2007 Jul; 130(Pt 7):1847-60. PubMed ID: 17412733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of levodopa treatment on contrast sensitivity in Parkinson's disease.
    Bulens C; Meerwaldt JD; Van der Wildt GJ; Van Deursen JB
    Ann Neurol; 1987 Sep; 22(3):365-9. PubMed ID: 3674801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid eye movement sleep behavior disorder preceding Parkinson's disease with therapeutic response to levodopa.
    Tan A; Salgado M; Fahn S
    Mov Disord; 1996 Mar; 11(2):214-6. PubMed ID: 8684394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Swept contrast visual evoked potentials and their plasticity following monocular deprivation in mice.
    Lickey ME; Pham TA; Gordon B
    Vision Res; 2004 Dec; 44(28):3381-7. PubMed ID: 15536006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.